


Enantioselective Silver-Catalyzed Cascade Synthesis of Fused Lactone- and Lactam-Oxazolines

Raquel de la Campa, Rubén Manzano,[†] Paul Calleja, Sam R. Ellis and Darren J. Dixon*

Department of Chemistry, Chemistry Research Laboratory, University of Oxford, 12 Mansfield Road, Oxford OX1 3TA, UK

Supporting Information Placeholder



ABSTRACT: A new and highly stereoselective cascade reaction between isocyanoacetate esters and α -hydroxy- and α -aminoketones has been developed. A cinchona alkaloid-derived aminophosphine/silver(I) catalyst complex promoted the reaction, and enabled the ready synthesis of fused bicyclic γ -lactone- and γ -lactam-oxazolines with high enantiocontrol (up to 99% ee).


Cascade reactions constitute an important resource efficient tool to rapidly build complex molecular architectures from simple starting materials, whilst reducing processing times and avoiding the need for isolation of intermediate compounds.^{1,2} In particular, the enantioselective synthesis of heterocycles via cascade processes has attracted considerable interest from the synthetic community. In this context, inspired by the seminal works of Hayashi, Ito, and Sawamura,³ our group has developed enantioselective silver-catalyzed reactions of isocyanoacetates with aldehydes, ketones and ketimines to afford enantioenriched oxazolines⁴ and imidazolines (Scheme 1a).⁵ The catalyst system, formed from a quinine-derived aminophosphine ligand and a silver(I) salt, is able to coordinate the isocyanoacetate and electrophile simultaneously to promote cyclization to the corresponding heterocycle in a highly enantiocontrolled fashion.^{5a} Analogous enantioselective transformations have been reported using Ag and other metals such as Cu and Ni.⁶

As part of our research programme into the development of new enantioselective complexity-generating reactions, we considered a multi-stage, one-pot cascade process between isocyanoacetates and ketones possessing pendant nucleophilic moieties, such as a hydroxy or an amino group. We envisaged that a chiral silver/ligand complex might initially catalyze an enantioselective aldol-


type reaction which, following cyclization, would result in oxazoline formation.

Scheme 1. Proposed cascade reaction of isocyanoacetates and α -hydroxy or α -amino ketones

a) Previous work³⁻⁶



b) This work



At this stage, the pendant nucleophilic group would then be positioned to react with the adjacent ester func-

tionality to afford fused bicyclic γ -lactone- or γ -lactam-oxazolines possessing a fully substituted β -carbon atom (Scheme 1b). Such cascade products would have the potential to be readily converted into α -amino- β -hydroxy- γ -lactones or γ -lactams, and therefore could be considered as masked polyhydroxylated α -aminoacids, which can be found in many biologically active antibacterial⁷ and antifungal⁸ drugs. Although several stereoselective syntheses of polyhydroxylated α -aminoacids and derivatives have been reported,^{9,10} a general enantioselective synthesis of β,γ -dihydroxy- α -aminoacid precursors to date has not been realized, and herein we wish to report our findings.

Preliminary studies to assess the feasibility of this cascade concept were performed employing 2-hydroxy acetophenone **2a** and methyl isocyanoacetate **3** as the model system. Building on our previous work,^{4,5} a range of silver salts, aminophosphine ligands, and other reaction parameters were investigated. Pleasingly, under previously reported conditions (Table 1, Entry 1) employing Ag₂O and the quinine-derived aminophosphine ligand **1a**, the *cis*-fused bicyclic γ -lactone-oxazoline (3*aS*,6*aS*)-**5a** was formed as the major product in good yield with excellent enantioselectivity (99% ee). In addition, monocyclic oxazoline **6a** was isolated as a minor reaction side-product.¹¹ EtOAc proved to be optimal as the solvent, with lower yields and enantioselectivities being obtained in other solvents (Entries 2 and 3), while changing temperature (Entries 4 and 5) or silver salt (Entries 6 and 7) offered no improvement. Importantly, use of the pseudoenantiomeric aminophosphine ligand **1b** led to formation of the enantiomeric product (3*aS*,6*aR*)-**5a** with excellent enantioselectivity (96% ee, Entry 8). Control reactions demonstrated that both Ag₂O and the aminophosphine ligand were required, as no reaction occurred in their absence (Entries 9 and 10 respectively). The reaction performed similarly well using ethyl isocyanoacetate **4**, with the product being formed in comparable yield and enantioselectivity (99% ee, Entry 11) to the reaction with **3**.

With the optimized conditions established, the scope of the cascade reaction was explored using methyl isocyanoacetate **3** and a variety of 2-hydroxyketones **2** (Scheme 2). The reaction proceeded with several *para*-substituted 2-hydroxyacetophenones possessing either electron-withdrawing or donating groups, **2b-2d**, and the corresponding fused γ -lactone-oxazolines (**5b-5d**) were obtained as the major products with good product selectivity (5/6 ratio) and excellent enantioselectivities (97-99% ee). The use of *meta*-substituted 2-hydroxyacetophenone **2e** afforded the bicyclic product **5e** with similar levels of enantiocontrol as compared to **5d**. Importantly, the use of *ortho*-substituted 2-hydroxyacetophenones **2f-2i** was well-tolerated and bicyclic oxazolines **5f-5i** were obtained with higher product selectivity (90:10 to 96:4) and yield compared to their corresponding *meta*- or *para*- equivalents. The products were also obtained with excellent enantioselectivity (90-99% ee).

1-Acetonaphthone derivative **2j** was an excellent substrate and afforded the *cis*-fused γ -lactone-oxazoline **5j**

with excellent product selectivity (>98:2) and with good enantioselectivity.

Table 1. Optimization of the cascade synthesis of fused bicyclic γ -lactone-oxazolines.^a

entry	change in conditions	5a (%) ^b	6a (%) ^b	5a/6a ratio ^c	ee 5a (%) ^d
1	None	55	25	74:26	99
2	CH ₂ Cl ₂	36	46	52:48	91
3	MeOH	50	43	54:46	14
4	-40 °C	46	24	72:28	94
5	0 °C	50	36	69:31	95
6	Ag ₂ CO ₃	52	16	73:27	96
7	AgOAc (5 mol%)	54	23	67:33	92
8	1b	40	20	66:34	96 ^e
9 ^f	No Ag ₂ O	-	-	-	-
10 ^f	No 1a	-	-	-	-
11	R=Et (4)	53	35 (7)	63:37	99


^a Conditions: Isocyanoacetate **3** (0.35 mmol), α -hydroxy ketone **2a** (1.1 equiv), Ag₂O (2.5 mol %) and ligand **1a** (5 mol %) in EtOAc (2 mL) at -20 °C for 16 h. ^b Yield of isolated product after flash column chromatography. ^c Ratio of **5a** and **6a** was determined by ¹H analysis of the crude reaction mixture. ^d Enantiomeric excess of **5a** was determined by HPLC analysis on a chiral stationary phase. ^e Enantiomeric product (3*aS*,6*aR*)-**5a** formed. ^f No reaction.

Heteroaromatic ketone **2k** also engaged in this reaction, affording oxazoline **5k** with good enantioselectivity, albeit with minimal diastereocontrol in the initial aldol reaction. Interestingly, sterically hindered alcohols such as the tertiary alcohol **2l** performed well, with **5l** being obtained with excellent enantioselectivity. The reaction could be readily extended to obtain bicyclic lactams, with the corresponding *cis*-fused γ -lactam-oxazoline product (**5m**) being obtained from the aniline-derived acetophenone **2m** with good enantiocontrol. In addition, enantiomeric products of **5a-5m** could be prepared by employing pseudoenantiomeric aminophosphine ligand **1b** with similar (albeit reduced) yields and enantioselectivities in most cases.

The absolute configuration of product **5g** (obtained using ligand **1a**) was established by single crystal X-ray dif-

fraction analysis,¹² and was in agreement with previous observations;^{5a} other products were assigned by analogy.

Scheme 2. Scope of the enantioselective cascade synthesis of fused bicyclic γ -lactone- and γ -lactam-oxazolines.^a




^a Conditions: Methyl isocyanoacetate **3** (0.35 mmol), α -hydroxy ketone **2** (1.1 equiv), Ag_2O (2.5 mol%) and ligand **1a** (5 mol%) in EtOAc (2 mL) at -20 °C. Yields given are of isolated product after flash column chromatography. 5/6 ratios were determined by ^1H NMR analysis of the crude reaction mixture. Enantiomeric excess of **5** was determined by HPLC analysis on a chiral stationary phase. Values in parentheses represent the reaction with ligand **1b** generating the enantiomeric product. ^b AgOAc (5 mol%) and **1a** (10 mol%) were used.

The absolute configuration of monocyclic oxazolines **6** was assigned by chemical correlation; treatment of **6e** and *ent-6e* with DBU afforded bicyclic oxazolines **5e** and *ent-5e* in 10% and 6% ee respectively, presumably through

epimerization adjacent to the ester and concomitant cyclization. See Supporting Information for further details.

The versatility of the fused γ -lactone-oxazoline bicyclic products was demonstrated by subjecting **5d** to acidic methanolic conditions, which afforded functionally dense and stereochemically defined α -amino- β -hydroxy- γ -lactone **8** without erosion of enantiopurity (Scheme 3).

Scheme 3. Application to the synthesis of α -amino- β -hydroxy- γ -lactones



In summary, we have developed a highly enantioselective synthesis of fused γ -lactone and γ -lactam-oxazolines from isocyanoacetate pronucleophiles and α -hydroxy or α -amino ketones, respectively. One carbon-carbon, two carbon-heteroatom bonds, and two stereogenic centres of the bicyclic product were created through a cascade reaction employing a silver(I)/aminophosphine catalyst system. Application to the synthesis of α -amino- β -hydroxy- γ -lactones was also demonstrated. Work to apply these findings to other enantioselective cascade reactions is ongoing in our laboratory and the results will be disclosed in due course.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.orglett.xxxxxx. All experimental details, copies of NMR spectra, and HPLC data (PDF)

Crystallographic information for compound **5g** (CIF)

AUTHOR INFORMATION

Corresponding Author

* E-mail: darren.dixon@chem.ox.ac.uk

ORCID

Darren J Dixon: 0000-0003-2456-5236

Sam Ellis: 0000-0003-1412-113X

Rubén Manzano: 0000-0001-7290-3979

Present Address

[†] Dr Rubén Manzano, Department of Organic Chemistry II, University of the Basque Country (UPV/EHU), P.O. Box 644, 48080 Bilbao (Spain)

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENT

The authors thank the EC for an IEF to R. C. (PIEF-GA-2012-329689) and to R. M. (PIEF-GA-2013-627232). SE is supported by the EPSRC Centre for Doctoral Training in Synthesis for Biology and Medicine (EP/L015838/1), generously supported by AstraZeneca, Diamond Light Source, Defence Science and

Technology Laboratory, Evotec, GlaxoSmithKline, Janssen, Novartis, Pfizer, Syngenta, Takeda, UCB, and Vertex. We thank Dr. Ángel Fuentes and Heyao Shi (University of Oxford) for X-ray structure determination, and Dr Amber L. Thompson and Dr Kirsten E. Christensen (Oxford Chemical Crystallography Service) for X-ray mentoring and help.

REFERENCES

- (1) *Catalytic Cascade Reactions*, Eds. Xu, P.-F.; Wang, W. Wiley, Hoboken, **2014**.
- (2) (a) Wang, Y.; Lu H.; Xu, P.-F. *Acc. Chem. Res.* **2015**, *48*, 1832. (b) Lu, L.-Q.; Chen, J.-R.; Xiao W.-J. *Acc. Chem. Res.* **2012**, *45*, 1278. (c) Grondal, C.; Jeanty, M.; Enders, D. *Nature Chem.* **2010**, *2*, 167. (d) Nicolaou, K. C.; Chen, J. S. *Chem. Soc. Rev.* **2009**, *38*, 2993. (e) Nicolaou, K. C.; Edmonds, D. J.; Bulger, P. G. *Angew. Chem. Int. Ed.* **2006**, *45*, 7134.
- (3) See for example: (a) Ito, Y.; Sawamura, M.; Hayashi, T. *J. Am. Chem. Soc.* **1986**, *108*, 6405. (b) Ito, Y.; Sawamura, M.; Hayashi, T. *Tetrahedron Lett.* **1987**, *28*, 6215. (c) Pastor, S.D.; Togni, A. *J. Am. Chem. Soc.* **1989**, *111*, 2333. (d) Sawamura, M.; Hamashima, H.; Ito, Y. *J. Org. Chem.* **1990**, *55*, 5935. (e) Hayashi, T.; Uozumi, Y.; Yamazaki, A.; Sawamura, M.; Hamashima, H.; Ito, Y. *Tetrahedron Lett.* **1991**, *32*, 2799. (f) Soloshonok, A.V.; Hayashi, T.; Ishikawa, K.; Nagashima, N. *Tetrahedron Lett.* **1994**, *35*, 1055. (g) Soloshonok, A. V.; Kacharov, D. A.; Hayashi, T. *Tetrahedron* **1996**, *52*, 245.
- (4) (a) Franchino, A.; Jakubec, P.; Dixon, D. J. *Org. Biomol. Chem.* **2016**, *14*, 93. (b) De la Campa, R.; Ortín I.; Dixon, D. J. *Angew. Chem. Int. Ed.* **2015**, *54*, 4895. (c) Sladojevich, F.; Trabocchi, A.; Guarna, A.; Dixon, D. J. *J. Am. Chem. Soc.* **2011**, *133*, 1710.
- (5) (a) De la Campa, R.; Gammack Yamagata, A. D.; Ortín, I.; Franchino, A.; Thompson, A. L.; Odell, B.; Dixon, D. J. *Chem. Commun.* **2016**, *52*, 10632. (b) Ortín I.; Dixon, D. J. *Angew. Chem. Int. Ed.* **2014**, *53*, 3462.
- (6) (a) Shao, P.-L.; Liao, J.-Y.; Ho, Y. A.; Zhao, Y. *Angew. Chem. Int. Ed.* **2014**, *53*, 5435-5439. (b) Tamura, K.; Kumagai, N.; Shibasaki, M. *Eur. J. Org. Chem.* **2015**, 3026. (c) Nakamura, S.; Yamaji, R.; Iwanaga, M. *Chem. Commun.* **2016**, *52*, 7462. (d) Liao, J.-Y.; Yap, W. J.; Wu, J.; Wong, M. W.; Zhao, Y. *Chem. Commun.* **2017**, *53*, 9067-9070. (e) Peng, X.-J.; Ho, Y. A.; Wang, Z.-P.; Shao, P.-L.; Zhao, Y.; He, Y. *Org. Chem. Front.* **2017**, *4*, 81-85.
- (7) For selected references on lysobactin, see: (a) Lee, W.; Schaefer, K.; Qiao, Y.; Srisuknimit, V.; Steinmetz, H.; Müller, R.; Kahne, D.; Walker, S. *J. Am. Chem. Soc.* **2016**, *138*, 100. (b) Guzman-Martinez, A.; Lamer, R.; Van Nieuwenhze, M. S. *J. Am. Chem. Soc.* **2007**, *129*, 6017. (c) Nussbaum, F. von; Anlauf, S.; Benet-Buchholz, J.; Häbich, D.; Köbberling, J.; Musza, L.; Telser, J.; Rübsamen-Waigmann, H.; Brunner, N. A. *Angew. Chem. Int. Ed.* **2007**, *46*, 2039. (d) Durhaler, R. O. *Tetrahedron* **1994**, *50*, 1539. For a reference on polyoxins, see: (e) Akita, H. *Heterocycles* **2009**, *77*, 67. For a reference on other nucleoside antibiotics, see: Knapp, S. *Chem. Rev.* **1995**, *95*, 1859.
- (8) For a reference on echinocandins, see: Bills, G.; Li, Y.; Chen, L.; Yue, Q.; Niuab, X.-M.; An, Z. *Nat. Prod. Rep.* **2014**, *31*, 1348.
- (9) For enantioselective syntheses of both enantiomers of 2-amino-3,4-dihydroxybutyric acid, see: (a) Swift, M. D.; Sutherland, A. *Tetrahedron* **2008**, *64*, 9521. (b) Fadnavis, N. W.; Sharfuddin, M.; Vadivel, S. K. *Tetrahedron: Asymm.* **2001**, *12*, 691.
- (10) Selected examples: (a) Gómez, R. V.; Kolender, A. A.; Varela, O. *Carbohydr. Res.* **2006**, *341*, 1498. (b) Davis, F. A.; Prasad, K. R.; Carroll, P. J. *J. Org. Chem.* **2002**, *67*, 7802. (c) Palomo, C.; Oiarbide, M.; Landa, A.; Esnal, A.; Linden, A. *J. Org. Chem.* **2001**, *66*, 4180. (d) Bose, A. K.; Banik, B. K.; Mathur, C. D.; Wagle, R.; Manhas, M. S. *Tetrahedron* **2000**, *56*, 5603. (e) Berkowitz, D. B.; Pedersen, M. L. *J. Org. Chem.* **1995**, *60*, 5368. (f) Suga, H.; Fujieda, H.; Hirotau, Y.; Ibata, T. *J. Org. Chem.* **1994**, *59*, 3359.
- (11) The relative configuration of **6a** was not directly determined, however the lack of reactivity of **6a** towards cyclization, even after prolonged reaction times (72 h), supports the *trans* relationship of the ester and hydroxymethyl groups.
- (12) Low temperature single X-ray diffraction data were collected for **5g** using a (Rigaku) Oxford Diffraction Supernova diffractometer. Data were reduced using CrysAlisPro and solved using Superflip [Palatinus, L.; Chapuis, G. *J. Appl. Cryst.* **2007**, *40*, 786] before within CRYSTALS [Betteridge, P. W.; Carruthers, J. R.; Cooper, R. I.; Prout, K.; Watkin, D. J. *J. Appl. Cryst.* **2003**, *36*, 1487; Cooper, R. I.; Thompson, A. L.; Watkin, D. J. *J. Appl. Cryst.* **2010**, *43*, 1100]. Full crystallographic data (in CIF format) are available as ESI and have been deposited in the Cambridge Crystallographic Data Centre (CCDC 1542388).